Abstract 710P
Background
Early-phase clinical trials are a unique opportunity for patients with cancer to benefit from innovative treatments. These trials usually demand newly-collected tumor tissue for research purpose, requiring patients to undergo new biopsies. Some trials require a prescreening by next-generation sequencing (NGS), but the analysis can be challenged by both the quality and the quantity of the samples. Biopsies may have procedural complications with negative impact on patients.
Methods
We retrospectively reviewed the records of patients referred to the Early Drug Development (EDD) Unit of European Institute of Oncology, who performed fresh biopsies for research purpose. We aimed at assessing safety of the biopsies and the adequacy of the tumor tissue for NGS testing.
Results
A total of 731 patients were referred to the EDD Unit from January 2014 to December 2022. Median age was 56 years (range 20 – 83) and 79% of patients were female. The most common tumor type was breast cancer (40%), followed by lung adenocarcinoma (6.2%), cholangiocarcinoma (5.8%), and carcinoma of unknown primary (5.8%). Three hundred fifty-five patients (48.6%) underwent a new biopsy at trial entry. Liver (148, 41.7%), lymph nodes (64, 18%), skin (47, 13.2%) and breast (7.3%) were the most frequent sites for biopsy. The median time from trial’s informed consent to biopsy was 3 days (range 0 – 83). The tumor tissue was commonly adequate for histological diagnosis (98%); NGS testing was successful in 122 (88.4%) of the 138 cases in which the trial required NGS testing. Nine out of the 16 unsuccessful NGS were performed on liver tissue. Eleven patients (3.1%) had procedural complications from the biopsy (5 pain, 3 minor bleeding, 2 pneumothoraxes, 1 bradycardia), but none required hospitalization nor led to sequelae. The only treatments administered were painkillers.
Conclusions
Approximately half of the patients referred to our EDD Unit performed a fresh biopsy. The procedure was generally safe, with only a minority of patients (3%) having non-serious complications. About 10% of NGS failed due to poor sample quality or quantity, highlighting the importance to implement specific information and Standard Operating Procedure for samples intended for NGS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Edoardo Crimini.
Funding
Has not received any funding.
Disclosure
D. Trapani: Other, EMA Healthcare Professional Working Party (HCPWP), member: European Medicines Agency (EMA); Other, EML Cancer Medicines Working Group (CMWG), member: World Health Organization (WHO); Other, Strategic Advisory Group of Experts on In Vitro Diagnostics (SAGE IVD), chair: World Health Organization (WHO). C. Criscitiello: Financial Interests, Personal, Invited Speaker: Pfizer, Novartis, Eli-Lilly, Roche, Gilead; Financial Interests, Personal, Advisory Board: MSD, Seagen, AstraZeneca, Daiichi Sankyo. G. Curigliano: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, Daiichi Sankyo, Novartis, Pfizer; Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Daiichi Sankyo, Lilly, Pfizer, Veracyte, BMS, Merck, Exact Sciences, Celcuity; Financial Interests, Personal, Writing Engagement: Pfizer; Financial Interests, Personal, Other, Advisory Board: Ellipsis; Financial Interests, Institutional, Research Grant, Investigator Initiated Trial: Merck; Financial Interests, Institutional, Funding, Phase I studies: BMS, Novartis, AstraZeneca, Daiichi Sankyo, Roche, Blueprint Medicine, Kymab, Astellas, Sanofi, Philogen; Financial Interests, Institutional, Coordinating PI, Phase I clinical basket trial: Relay Therapeutics; Non-Financial Interests, Member of Board of Directors, No compensation for this role. This a public national company for cancer prevention: Lega Italiana Lotta ai Tumori; Non-Financial Interests, Officer, Italian National Health Council as Advisor for Ministry of Health: Consiglio Superiore di Sanità; Non-Financial Interests, Advisory Role, Member of the Scientific Council. Patient advocacy association: Europa Donna; Non-Financial Interests, Advisory Role, Cancer Research Foundation: Fondazione Beretta; Non-Financial Interests, Officer, Member of the Advisory Council: EUSOMA; Non-Financial Interests, Officer, ESMO Clinical Practice Guidelines Chair: ESMO. All other authors have declared no conflicts of interest.
Resources from the same session
126P - Biliary tract cancer (BTC) characterization on a cohort of patients (pt) from the Spanish RETUD Registry
Presenter: Adelaida Lacasta
Session: Poster session 17
127P - Prognostic significance of intratumoral and peritumoral budding in distal extrahepatic bile duct carcinoma
Presenter: Sun-Young Jun
Session: Poster session 17
128P - Biliary tract cancers: Epidemiological and prognosis trends of Latin American population
Presenter: Maria del Consuelo Diaz Romero
Session: Poster session 17
129P - Prognostic factors associated with survival in resected biliary tract cancers: A multicentre Italian experience
Presenter: Michele Ghidini
Session: Poster session 17
663P - Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC
Presenter: Carlos Rojas
Session: Poster session 17
664P - Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors
Presenter: Ryan Corcoran
Session: Poster session 17
666P - Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours
Presenter: Shun Lu
Session: Poster session 17
667P - Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer
Presenter: David Hong
Session: Poster session 17